{"name":"Patrick Y. Wen, MD","slug":"patrick-y-wen-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SOM230C","genericName":"SOM230C","slug":"som230c","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"SOM230C","genericName":"SOM230C","slug":"som230c","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOZF9Ranl3NkJ1dVhPbFJRRzQzbUhSNzUxUU8yS0huc2RWcE0wdjVkbXpsOWFHeEFDcEx2dHBGdmNuazh3RWJ5bFpzMDdaVy1FYXgtQS1FenJhME1POU05dVI3RVVhZ2QtaXdBM2EtbS00bS1RUEcxNWxrSlgtWkhZeUFfd0ZaR05KME1qVVJiTlZvMm0wUXY3eWRxaWNmejlUUkFWNkFoOWdsV1N5LXV2ZUZqVQ?oc=5","date":"2025-08-07","type":"regulatory","source":"Oncology News Central","summary":"FDA Approves First Drug for H3 K27M-Mutated Diffuse Midline Glioma - Oncology News Central","headline":"FDA Approves First Drug for H3 K27M-Mutated Diffuse Midline Glioma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1xblhlSlU0VzNyTEs5N2MwV3N6M0lpS21rdUZlcWdGRFAteTFyNWZpZHU1cXo0LVIyZWVjRVNidHpabDNmUXZQTjVtdk15ZXM5LUg4Mk9HMndsMGhiY1I3QVhnajJGZEtydXc?oc=5","date":"2023-12-25","type":"pipeline","source":"Neurology® Journals","summary":"Seizures Among Patients With Brain Metastases - Neurology® Journals","headline":"Seizures Among Patients With Brain Metastases - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPMm5fX2wyUk9lOU53bk1kcUY3cEJJQmNFN2FtM2xid083UjY1MGpLMzZfWWt5cUFaM1N4QTlpSy1qTURqaFJFbjViakFaZExSTnFRNFdsOXMxTERmdGM2WFBON0pQUldRazQ3NWdlRFhRemIxRGJYYjZBemdyOFNNRDRlOHlENUxReGhXRVA4SGhKN3VUTFBaUlZSOVVZX0VHUU1kcEFqbWhvbGhhLVJUZg?oc=5","date":"2023-12-18","type":"pipeline","source":"OncLive","summary":"Dr Wen on the Evaluation of Vorasidenib in IDH1- and IDH2-Mutated Low-Grade Glioma - OncLive","headline":"Dr Wen on the Evaluation of Vorasidenib in IDH1- and IDH2-Mutated Low-Grade Glioma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPUDkyaWNGbUFrSmxRdUxGb0NDaUxaVExsTFhjMXhCQjRIVFBXbkx4bWp5dTJWRk05dDByMkE3XzZHcXRwX1dmSmlJRElzZzdkTl9yMmpwU3k3TmNDc0xaNGRTMERVMExVbmdhU0dqRE90WVdYVDlSN193UTBHaEhCX041NlZnOW8?oc=5","date":"2022-03-30","type":"pipeline","source":"OncLive","summary":"Targeted Combo Notches Rare Success in Glioblastoma - OncLive","headline":"Targeted Combo Notches Rare Success in Glioblastoma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}